The FDA has approved Avance® (acellular nerve allograft-arwx) for treating sensory nerve discontinuity. Derived from cadaveric nerve tissue, Avance bridges gaps in injured peripheral nerves to restore function. Its processing removes cellular components to minimize rejection risk.

Avance is a peripheral nerve scaffold approved for sensory nerve discontinuities (≤25mm) (breaks in the pathway of sensory nerves) in adults and pediatric patients aged one month and older. Under the Accelerated Approval pathway, Avance is also approved for larger sensory nerve discontinuities (>25mm), motor and mixed nerve discontinuities.

Avance was studied in patients with sensory nerve discontinuities and additional investigations of mixed and motor nerve discontinuities.

“Avance can bridge gaps in damag

See Full Page